This chapter aims at dealing with the state-of-the-art novelty of AI with microbial nanomaterials in vaccination aspect to tackle the global cardiovascular crisis of antibiotics resistance. It discusses the necessity of precision progress solutions and detailed types of microbial nanomaterials such as bacterial nanocellulose, bacteriophages, and exopolysaccharides. From biofilm disruption to targeted antimicrobial delivery mechanisms, the ability for AI to design and optimize the structure and composition of these things at the nanoscale level is groundbreaking. AI, thus, increases the flexibility of microbial nanomaterials to mitigate the evolving threat of antibiotic-resistant strains as it aids in real time adaptation to resistant challenges. Some case studies highlight its efficiency: bacterial nanocellulose gains unprecedented precision for wound healing through dynamic adjustment of its composition; AI-guided bacteriophages show improved specificity and flexibility against resistant microbes; and AI-designed exopolysaccharides can have improved biofilm inhibition. It also discusses ethical pitfalls and the importance of transparent algorithms and responsible AI. It urges an equilibrium of potential risks and benefits to responsibly harness AI’s potential. However, in future, the convergence of AI with microbial nanomaterials may accelerate developments in tailored therapeutics, precision medicine, and real-time responsiveness. This hybrid strategy may usher in a new paradigm in the battle against increasing antibiotic resistance through the complementary use of computer-based intelligence along with the distinctive characteristics of microbial nanostructures for targeted, efficient, and versatile therapeutic options.